- Home
- DRD vs TSHA Comparison
DRD vs TSHA Comparison
Compare DRD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRD
- TSHA
- Stock Information
- Founded
- DRD 1895
- TSHA 2019
- Country
- DRD South Africa
- TSHA United States
- Employees
- DRD N/A
- TSHA N/A
- Industry
- DRD Precious Metals
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- DRD Basic Materials
- TSHA Health Care
- Exchange
- DRD Nasdaq
- TSHA Nasdaq
- Market Cap
- DRD 1.6B
- TSHA 1.3B
- IPO Year
- DRD N/A
- TSHA 2020
- Fundamental
- Price
- DRD $27.69
- TSHA $5.02
- Analyst Decision
- DRD Strong Buy
- TSHA Strong Buy
- Analyst Count
- DRD 2
- TSHA 8
- Target Price
- DRD $24.63
- TSHA $9.38
- AVG Volume (30 Days)
- DRD 1.1M
- TSHA 11.4M
- Earning Date
- DRD 01-01-0001
- TSHA 11-12-2025
- Dividend Yield
- DRD 1.56%
- TSHA N/A
- EPS Growth
- DRD 68.66
- TSHA N/A
- EPS
- DRD 1.46
- TSHA N/A
- Revenue
- DRD $443,674,785.00
- TSHA $8,098,000.00
- Revenue This Year
- DRD $10.81
- TSHA N/A
- Revenue Next Year
- DRD $20.03
- TSHA N/A
- P/E Ratio
- DRD $19.73
- TSHA N/A
- Revenue Growth
- DRD 26.26
- TSHA N/A
- 52 Week Low
- DRD $8.38
- TSHA $1.05
- 52 Week High
- DRD $30.36
- TSHA $5.40
- Technical
- Relative Strength Index (RSI)
- DRD 62.05
- TSHA 73.34
- Support Level
- DRD $28.37
- TSHA $4.32
- Resistance Level
- DRD $30.36
- TSHA $5.40
- Average True Range (ATR)
- DRD 1.42
- TSHA 0.34
- MACD
- DRD -0.16
- TSHA 0.19
- Stochastic Oscillator
- DRD 41.18
- TSHA 85.47
About DRD DRDGOLD Limited
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields; and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.